ArticlePediatric cardiology2026
Konar-MF ™: Versatile Utility Suggests Potential to Simplify Congenital Catheterization Laboratory Inventory.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
KONAR-MF™ device is a novel, cone-shaped, medium profile, self-expanding, double-disk, nitinol occlusive device designed for the ventricular septal defect (VSD). Due to its unique design and easy deployment from either side and multiple occlusion layers, it has also been used to occlude defects other than VSD. A retrospective review was done from 2019 to 2024 from three institutions. All patients where the KONAR-MF™ device was used other than for VSD closure were included in this study. Standard post-procedure follow-up was at 1, 6, and 12 months for all patients. 79 off-label implantations of the KONAR-MF™ device were done for conditions that included 59 shunt lesions (patent ductus arteriosus -34, coronary arteriovenous fistula -12, pulmonary arteriovenous fistula -2, systemic arteriovenous fistula -3, aortopulmonary window -3, aortopulmonary collateral -5, Fontan fenestration closures -7, Fontan antegrade pulmonary valve closures -2, Abernethy malformations -3, decompressing vein -2, and paravalvular leak -2, others 4. The median fluoroscopy time was 10 min (IQR 6-18). The median duration of hospital stay was 2 days (IQR 1-4 days). There were no significant complications. Complete occlusion at the end of the procedure was documented in 72 (91.13%) patients. At a median follow-up of 18 months (IQR 12-28 months) in all except one patient who had mild residual flow with no device-/(procedure) related complications. The unique structure and compact profile of KONAR-MF™ enable a wide range of uses in catheter-based management of various CHDs with the potential to simplify the inventory of the catheterization laboratory.
Indexed as
Identifiers
40185938What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.